Business
Imara Reports Third Quarter 2021 Financial Results and Business Highlights
Interim analysis data for Phase 2b clinical trials of tovinontrine (IMR-687) in patients with beta-thalassemia and sickle cell disease expected in fourth
About this update from Enliven Therapeutics, Inc.
[{"type":"text","content":" Interim analysis data for Phase 2b clinical trials of tovinontrine (IMR-687) in patients with beta-thalassemia and sickle cell disease expected in fourth quarter of 2021 Introduction of pipeline program IMR-261, a novel oral clinic-ready Nrf2 activator shown to reactivate fetal hemoglobin and reduce VOCs in preclinical models of sickle cell disease Building team for planned HFpEF Phase 2 trial, led by hiring of Dr. Toni Bransford, a seasoned cardiologist and heart failure clinical developer Company to host conference call and live webcast today at 8:30 AM ET BOSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today reported financial results for the third quarter ending September 30, 2021 and reviewed recent business highlights. “Following the completion of enrollment in both our Ardent trial of tovinontrine (IMR-687) for sickle cell disease (SCD) and in the transfusion-dependent thalassemia (TDT) cohort of our Forte trial of tovinontrine for beta-thalassemia, we remain on track to report interim analysis data from these higher dose trials in the fourth quarter of 2021. Furthermore, we expect to report data from the primary analysis of the Ardent trial and to conduct a key efficacy analysis in TDT patients in the Forte trial in the first quarter of 2022,” said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara. “We also expect to present 12-month VOC data from our ongoing Phase 2a open label extension study of tovinontrine in patients with sickle cell disease at the American Society of Hematology (ASH) Annual Meeting to be held December 11-14, 2021.” Dr. Ballal continued, “I also am pleased to introduce our newest pipeline asset, IMR-261, a clinic-ready oral activator of nuclear factor erythroid 2–related factor 2, or Nrf2. We are excited about the potential for this compound, which the medical literature suggests has promise in a broad array of red blood cell diseases, including disorders of hemoglobin. We are also looking forward to presenting key preclinical data on IMR-261 in an oral presentation at the ASH Annual Meeting. Finally, we are excited about the potential for tovinontri...